$200K Saved With First-Line Docetaxel for Prostate Cancer $200K Saved With First-Line Docetaxel for Prostate Cancer
For the first time, there is a cost-effectiveness study on two systemic drugs used in the treatment of newly diagnosed metastatic prostate cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | Prostate Cancer | Study | Taxotere